Consultation record
Submissions accepted — page 2
The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Submissions
681 documents · page 2 of 23
Table 1. Submissions with this disposition, on this page.
| Reference | Consultation | Respondent | Point raised |
|---|---|---|---|
| DRAFT-TIRZEPATIDE-/012 | Draft monograph: tirzepatide, version 2 | Dr Frideswide Hazelrigg | What happens when the compound is stopped is not addressed |
| DRAFT-TIRZEPATIDE-/003 | Draft monograph: tirzepatide, version 2 | Dr Jolanta Uttridge | Doses are expressed in units that differ between sections |
| DRAFT-TIRZEPATIDE-/004 | Draft monograph: tirzepatide, version 2 | Dr Georgiana Mountstephen | The compound is supplied under names the monograph does not list |
| DRAFT-TIRZEPATIDE-/015 | Draft monograph: tirzepatide, version 2 | Dr Zofia Petrossian | The absence of a rare harm in the trial set is presented as reassurance |
| DRAFT-TIRZEPATIDE-/009 | Draft monograph: tirzepatide, version 2 | Dr Amara Vandergraaf | The population to which the headline estimate applies is not stated with the estimate |
| DRAFT-TIRZEPATIDE-/014 | Draft monograph: tirzepatide, version 2 | Dr Thaddeus Isaksen-Balogun industry | Two factual descriptions of the sponsor's programme are inaccurate |
| DRAFT-BPC-157-MONO/003 | Draft monograph: BPC-157 | Dr Oswin Yorkstone | The pharmacokinetic section does not connect half-life to the dosing schedule |
| DRAFT-BPC-157-MONO/004 | Draft monograph: BPC-157 | Dr Kamila Ubertini | Absence of evidence is presented in a form a reader will take as negative evidence |
| DRAFT-BPC-157-MONO/006 | Draft monograph: BPC-157 | Dr Theodora Ingelbrecht | The monograph does not tell a reader that a stated mass may be substantially counter-ion and water |
| DRAFT-BPC-157-MONO/001 | Draft monograph: BPC-157 | Dr Delphine Trelawney | The absence of a rare harm in the trial set is presented as reassurance |
| DRAFT-BPC-157-MONO/002 | Draft monograph: BPC-157 | Dr Quentin Whitmarsh-Obi | What happens when the compound is stopped is not addressed |
| DRAFT-BPC-157-MONO/005 | Draft monograph: BPC-157 | Dr Quintus Kettlewell | Every contributing trial shares one sponsor and the monograph does not say so |
| DRAFT-BPC-157-MONO/008 | Draft monograph: BPC-157 | Dr Ottoline Oppenheimer-Ade | The population to which the headline estimate applies is not stated with the estimate |
| DRAFT-WEIGHT-REGAI/008 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Bertrand Steenkamp-Ferreira | The search date is not on the face of the document |
| DRAFT-WEIGHT-REGAI/005 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Katarzyna Oppenheimer-Ade industry | Two factual descriptions of the sponsor's programme are inaccurate |
| DRAFT-WEIGHT-REGAI/016 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Theodora Ximenes | The same concept is given three different names in one document |
| DRAFT-WEIGHT-REGAI/002 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Torvald Kettlewell | A funnel plot is presented for a set too small to interpret it |
| DRAFT-WEIGHT-REGAI/013 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Delphine Trelawney | Efficacy outcomes are rated for certainty and harms are not |
| DRAFT-WEIGHT-REGAI/014 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Quentin Whitmarsh-Obi | Analytical surveys are treated as evidence about suppliers when they establish only what was in a… |
| DRAFT-WEIGHT-REGAI/011 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Hortensia Larsson-Ekwueme | Registered trials that never reported are not counted anywhere in the review |
| DRAFT-WEIGHT-REGAI/004 | Draft synthesis: weight change after discontinuation of an incretin… | Dr Vittoria Ylönen | Intention-to-treat and efficacy-estimand results are combined without distinction |
| DRAFT-NETWORK-TRAN/001 | Draft methodological review: transitivity in the incretin network | Dr Eamon Immelmann | Studies using different outcome definitions are pooled into one estimate |
| DRAFT-NETWORK-TRAN/002 | Draft methodological review: transitivity in the incretin network | Dr Liesbeth Zaleski-Mbeki | Absence of evidence is presented in a form a reader will take as negative evidence |
| DRAFT-NETWORK-TRAN/003 | Draft methodological review: transitivity in the incretin network | Dr Liesbeth Delacroix-Njoku | The review does not say when it will be updated or what would trigger an update |
| DRAFT-NETWORK-TRAN/009 | Draft methodological review: transitivity in the incretin network | Dr Hamish Nyquist-Obiora | Results at materially different follow-up durations are pooled |
| DRAFT-CONFLICTS-PO/010 | Draft conflicts-of-interest policy | Rosalind Petrossian | An industry submission should be identifiable without reading the declared interest |
| DRAFT-CONFLICTS-PO/011 | Draft conflicts-of-interest policy | Dr Hyacinth Oyelaran-Steen | The search date is not on the face of the document |
| DRAFT-CONFLICTS-PO/002 | Draft conflicts-of-interest policy | Dr Zebedee Zaleski-Mbeki | The terms on which the documents may be reused are not stated |
| DRAFT-FUNDING-POLI/008 | Draft funding and sponsorship policy | Dr Matthias Whitmarsh-Obi | The terms on which the documents may be reused are not stated |
| DRAFT-FUNDING-POLI/010 | Draft funding and sponsorship policy | Dr Fenella Lavrentiev | The same concept is given three different names in one document |
page 2 of 23